Participating in a clinical trial can be a life-changing experience. When you join a clinical trial, you not only take an active role in fighting your own cancer, but you also help researchers and scientists develop new medications and treatments to help other cancer patients live longer.

 

At The Christ Hospital Health Network, we are recognized as a national leader in clinical research and for best practice standards in patient care. Our research and innovation has led to breakthrough medical advances and improved outcomes for nearly 40 years.

 

Every day, our doctors and researchers work to find cures for cancer - but we don't do it alone. Our patients play an essential role in finding better ways to prevent, diagnose and treat cancer.

 

Promising new therapies for cancer

Our clinical trials are conducted at various locations including:

  • The Christ Hospital Cancer Center

  • The Christ Hospital Physicians - Hematology & Oncology

  • The Christ Hospital Physicians - Surgical Oncology

  • Other clinical sites throughout Greater Cincinnati

We average 15 active studies, from phase I though phase IV. Phases are steps that clinical trials go through. If a new treatment is successful in one phase, it moves on to testing in the next phase.

 

Search our clinical trials

Find a clinical trial that is right for you. Below is a categorized list (alphabetical by cancer type) of all of our studies updated monthly so you know you're getting the latest information available. All of the following trials are currently recruiting. To refer a patient or enroll in a currently recruiting cancer cohort, call a research nurse at the Lindner Research Center at 513-585-1777.

  • Breast Cancer

  • Head & Neck

  • Lung Cancer

  • Leukemia/Lymphoma

  • Melanoma & Skin Cancer

All Newly Diagnosed, Untreated Cancer Patients


NCT2889978

The Circulating Cell-free Genome Atlas Study (CCGA)

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.


Breast Cancer


NCT01872975

NSABP B-51/RTOG 1304, is a Phase III, multicenter, randomized post neoadjuvant therapy trial, to evaluate whether the addition of chest wall and regional nodal external radiation therapy (XRT) after mastectomy, or, breast and regional nodal XRT after breast conserving surgery, will significantly reduce the rate of events for invasive breast cancer recurrence-free interval in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

NCT01674140

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

This randomized, phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. It compares whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer.

NCT01901094

 A011202 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

NCT01905046

A211102 Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better. 

Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If the patient is eligible to take tamoxifen, he/she must be offered tamoxifen prevention as part of clinical care. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen. Metformin is not approved for preventing breast cancer, but is currently being tested to determine if it can prevent breast cancer.

Head & Neck


NCT03237325

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck. Protocol Number:  IDR-OM-02-USA. The purpose of this study is to assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving fractionated radiation treatments and concomitant cisplatin chemotherapy, given as 80-100 mg/m2 every third week, for the treatment of squamous cell carcinoma of the oral cavity or oropharynx.

Lung Cancer


NCT03382899

CYPRESS-1/AM0010-201 is an open-labeled randomized Phase 2 trial of AM0010 in combination with Pembrolizumab vs. Pembolizumab alone as first-line therapy in patients with Stage IV/Metastatic Non-Small Cell Lung Cancer with high expression of PD-L1 (> 50%). The purpose of this study is to compare efficacy of AM0010 in combination with Pembolizumab vs Pembolizumab alone.

NCT03382912

CYPRESS-2/AM0010-202 is an open-labeled randomized Phase 2 trial of AM0010 in combination with Nivolumab vs. Nivolumab alone as second-line therapy in subjects with stage IV/metastatic wild type non-small cell lung cancer and low tumor expression of PD-L1. The purpose of this research study is to compare efficacy of AM0010 in combination with Nivolimab  vs Nivolimab alone. 

NCT02477826

BMS CA209816 is a randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in early stage non-small cell lung cancer. The purpose of this study is to test the effectiveness safety, and tolerability of Nivolumab in combination with Ipilimumab or Nivolumab in combination with platinum doublet chemotherapy as compared to platinum doublet chemotherapy alone in subject with non-small cell lung cancer. 

NCT03477474

GEODE 01-MX-003 is a registry of Guardant 360 use and outcomes in patients with advanced non-small cell lung cancer. The purpose of this study is to learn about the frequency and variety of tumor genetic mutations. More specifically how these findings effect clinical decisions made for each patient and the clinical outcomes associated with therapies selected when based on a mutation. 

Leukemia/Lymphoma


NCT03420183

Oncternal CIRM-001 is a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies. Cirmtuzumab is a novel therapeutic monoclonal antibody that targets ROR1, an onco-embryonic factor, expressed at high levels on CLL/SLL, MCL, and other tumors but not on normal adult tissues Nonclinical data support the development of cirmtuzumab together with ibrutinib to enhance antitumor activity, overcome disease resistance, and improve both short- and long-term outcomes for patients with CLL/SLL and MCL. The purpose of this study is to evaluate the safety and effectiveness of Cirmtuzumab, an investigational drug, which currently is not approved by the FDA.  It will be looked at alone as a single agent and in combination with ibrutinib, an FDA approved drug, in treating CLL/SLL or MCL.

Melanoma & Skin Cancer


NCT03597282

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) orIpilimumab with Nivolumab in Patients with Advanced or Metastatic Melanoma. Protocol Number: NT-003. 

The purpose of this study is to evaluate the safety of administering NEO-PV-01 using different regimens as well as in combination with APX005M or ipilimumab with nivolumab in patients with  metastatic melanoma. Durations of treatment with NEO-PV-01,APX005M, ipilimumab, and adjuvant will vary, depending on Cohort and Treatment Arm and will range between 24 and 48 weeks. Nivolumab will be administered throughout the study.  


NCT3142334

Merck 3475 - 000716 is an Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma. : A Randomized, Double-blind Phase III Study (KEYNOTE 716). This is a randomized, placebo-controlled, parallel-group, crossover/rechallenge, multi-center study of adjuvant pembrolizumab  in participants with resected Stage IIB or IIC cutaneous melanoma. Stage IIB and IIC cutaneous melanoma are defined as T category T3b, T4a, or T4b with negative sentinel lymph node biopsy, no regional metastases and no evidence of distant metastasis. The purpose of this study is to see how well the study drug, pembrolizumab, works compared to placebo in keeping cancer from coming back or spreading, test the safety of the study drug, and to see how the  body handles the study drug.

NCT03445533

IDERA 2125-MEL-301 is a Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab alone in subjects with Anti-PD-1 refractory melanoma. To compare the efficacy (measured by overall survival and overall response rate of intratumoral IMO-2125 in combination with Ipilimumab versus Ipilimumab alone.